Clinical trial
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe…
NCT00072943 · Facet Biotech, Industry · Completed
Key facts
| NCT number | NCT00072943 |
|---|---|
| Title | A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease |
| Official title | A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) Administered to Patients With Moderate to Severe Crohn's Disease |
| Lead sponsor | Facet Biotech, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease, Digestive System Disease |
| Intervention type | Drug |
| Interventions | anti-Interferon-gamma monoclonal antibody |
| Enrollment | 175 |
| Start date | Mar 1, 2002 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | Nov 17, 2003 |
| Last update posted | Mar 13, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: